Patients on B-cell depleting therapies at risk for breakthrough COVID-19, severe outcomes

Patients with immune-mediated inflammatory diseases receiving B-cell depleting therapies are at risk for COVID-19 regardless of vaccine status, but outpatient use of monoclonal antibodies improves clinical outcomes, according to data.

Read the full article here

Related Articles